Palavra-chave: CHRONIC MYELOID LEUKEMIA

HMGCLL1 DISCONTINUATION BCR-ABL PERIPHERAL BLOOD STEM CELL TRANSPLANTS IMATINIB-RESISTANT T315L ENESTND STATE UNIVERSITY OF CAMPINAS START COVID19 CLINICAL TRIAL CML SUBOPTIMAL RESPONSES INTERFERON-ALPHA AUTOGRAFTING NEW DRUGS JAK2 V617F ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION EUTOS SCORE IMATINIB RESISTANCE GENE EXPRESSION PROFILE SECOND-GENERATION BRAZILIAN MEDICAL ASSOCIATION EBMT DHPLC MOLECULAR RESPONSE B3A2 GLEEVEC CYTARABINE IRS-1 OCULAR DENATURING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY BCR-ABL1 IMATINIB STEM CELL TRANSPLANTATION P190, P120, P230 AUTOGRAFTING OF PERIPHERAL-BLOOD TYROSINE KINASE EXPANDING NILOTINIB ACESS IN CLINICAL TRIALS POLYMORPHISMS MOLECULAR CHRONIC PHASE TRANSPORTER GENES FEDERAL UNIVERSITY OF MINAS GERAIS D-HPLC DASATINIB-TREATED IMATINIB-RESISTANT OR-INTOLERANT DASATINIB MITOXANTRONE PROGRESSION-FREE SURVIVAL NON-MYELOABLATIVE FISH LASOR IMATINIB MESILATE CYTOGENETIC K562 CELLS NILOTINIB F359V MUTATION RT-PCR PHASE 2 EXPRESSION PF P190 TYROSINE KINASE INHIBITORS BONE MARROW TRANSPLANTATION EXON 6 T315I PH CHROMOSSOME EBMT RISK SCORES TK INHIBITORS TREATMENT-FREE REMISSION